ORSERDU™ (Elacestrant) is a targeted therapy designed for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This medication works by inhibiting the estrogen receptor, which is a key driver of cancer cell growth. It is particularly useful for patients who have not responded well to previous endocrine therapies. The drug is available in oral tablet form and is typically administered once daily with food.

ORSERDU™ has been approved for use in postmenopausal women and adult men. However, careful monitoring is required during treatment due to potential side effects such as liver toxicity and dyslipidemia. It is essential to assess liver function regularly and to adjust doses based on the severity of side effects or drug interactions.